Frictionless Mass Adoption
Eliminating painful swabs removes the biggest barrier to both consumer adoption and at-home regulatory clearance.
Investor Overview
Hero Scientific™: A Non-Invasive Sampling Breakthrough for Mass-Market Home Diagnostics
Our proprietary liquid concentrator replaces invasive swabs, turning painless liquid samples into lab-grade results to break the barrier to widespread adoption.
How the Concentrator Works
A 30-second, disposable device that turns a painless liquid sample into a lab-grade one.
No lab equipment required.
The Challenge
Sample collection is the single biggest challenge in home diagnostics.
Accurate results demand invasive collection: a painful urethral swab for STIs, a gag-inducing throat swab for strep. The FDA won't clear at-home tests built on methods this invasive, so the most needed tests stay locked in the clinic.
The Hero Solution
The Diagnostic Holy Grail: Lab-Grade Accuracy from a Painless Home Sample.
Lab-Grade Precision. Instrument-Free.
We are the first technology that instantly enriches a biological fluid home sample into a highly concentrated diagnostic target. Our device replicates the processing capabilities of a clinical laboratory, completely bypassing traditional lab machinery.
Unlocking Untapped High-Value Markets
Our platform enables an entirely new class of diagnostics by transitioning testing that was previously confined to centralized laboratories. Resolving the sample collection bottleneck allows these complex, high-value tests to safely enter the mass market for the first time.
Adoption & usability
A swab-free gargle children can do - the painless sample that unlocks mass-market home testing.
Applications & Market Size Estimates
One Platform Across High-Volume, Diverse Global Industries
Current focus
Sexual Health (STIs)
$3.20B TAM
2026 · Global At-Home STI Testing Market · projected to reach $5.90B by 2033 (8.9% CAGR)
Note: the decentralized, home-use subset of Fortune Business Insights' total $11.97B global STI market.
Source: Grand View Research (2026 Market Estimate)
Strep A
$1.25B TAM
At-home strep testing opportunity · company estimate (bottom-up): 50% of US pharyngitis cases × at-home test price · no FDA-cleared at-home test exists today
Source: Company estimate, bottom-up TAM
Near-term R&D pipeline *
Food Pathogen Testing
$6.6B TAM
2026 · Molecular (PCR / isothermal) food pathogen testing · part of the fastest-growing testing segment (~9% CAGR)
Source: MarketsandMarkets
Tuberculosis Diagnostics
$2.70B TAM
2026, projected to reach $4.08B by 2034 · oral/gargle sampling is our entry angle
Source: Precedence Research
Bovine Mastitis
$2.3B TAM
2026, projected to reach $4.0B by 2035 · plus $32B in annual dairy losses
Figures are 2026 total addressable market (TAM) estimates; sources noted per program.
Go to market
One Platform - Parallel Routes to Market
Our direct-to-consumer brand and B2B enterprise licensing.
Consumer flagship
A planned line of integrated, swab-free home tests distributed directly to consumers, starting with Strep and STI diagnostics. Following promising early clinical feasibility trials, we overhauled our platform’s chemistry and architecture to maximize sensitivity—with next-generation feasibility studies commencing Q4 2026.*
* In development. Integrated tests are not yet cleared or approved by the FDA.
Licensing & OEM
Licensing our sample-concentrator module to diagnostic leaders seeking higher sensitivity for existing molecular and lateral-flow platforms. High-value B2B applications span veterinary health, food safety, bovine mastitis, tuberculosis, and enterprise human diagnostics.
The consumer flagship
Swab-free, in a 3-5 second gargle.
The first and only swab-free home strep test. No driving, no waiting rooms, no throat jab.
In development. Not approved by the FDA.
A True Platform
One platform. Modular design. Endless applications.
A single, sample-agnostic device adapts across human health, animal health, and food safety, integrating seamlessly with leading diagnostic modalities—including molecular PCR and lateral flow test strips. Our current pipeline represents just our immediate R&D focus; the same core platform can power countless future applications.
Applicable across
- Human health
- Animal health
- Food safety
- Liquid biopsy
Compatible with
- Lateral-flow test strips
- Molecular / PCR
Deployable in
- Home (OTC)
- Clinic (PoC)
- Collection kit for lab processing
Patent Protection
Comprehensive intellectual property coverage across the core device architecture, proprietary filtration, and sample handling mechanisms.
11
Patent Families
7
Countries Protected
9
U.S. Patents Issued
12-Month Strategic Roadmap
Platform Industrialization, Validation & Commercial Strategy
Roadmap Fundamentals
Capital Runway
Our active $3M equity financing round is designed to fund our operational runway through pilot plastic injection mold production, small-scale manufacturing setup, and robust multi-vertical clinical data generation. Crucially, this capital enables wide engagement with the industry to generate deep awareness and commercial interest across multiple industry verticals.
Note: small-scale plastic injection molds are utilized solely for clinical and validation units; they do not represent final capital-intensive mass tooling.
Operational Transition
Device development transitions immediately from final design freeze into pilot injection tooling. This enables initial component delivery, running through November 2026 and supplying small-scale production and parallel clinical feasibility trials in December 2026. During this phase, we will test multiple detection platforms alongside our Hero Concentrator™ to gather broad performance data and share key learnings across the industry.
Strategic Horizon
Validating clear market demand across multiple industries establishes the commercial pull investment banks require. Reaching these early industry milestones sets us up to retain an investment bank, kicking off a structured process to maximize platform value.
12-Month Operational Timeline Matrix
Strategic Tracks
Q3 2026
Jul - Sep
Q4 2026
Oct - Dec
Q1 2027
Jan - Mar
Q2 2027
Apr - Jun
Q3 2027
Jul - Sep
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
1. Finance & Strategy
$3M Financing Round
Engage Banker
2. Mfg & Production
DFM (Jul)
Plastic Injection Molds & Components (Aug - Nov)
► Small-Scale Production (Starts Dec)
3. Clinical Validation
Strep A clinical feasibility trial (Dec 2026 - Jun 2027)
STI clinical feasibility trial (Dec 2026 - Jun 2027)
4. B2B Partnerships & Adjacent Apps
Explore Alternative Applications (Starts Oct)
B2B Industry Engagement (Starts Nov)
Corporate Strategy
Manufacturing & Assembly
Regulatory / Trial Data
Partnerships & Applications
Detailed Strategic Breakdown
Operational Execution
-
Phase 1: Design Freeze, DFM & Tooling (July – Nov 2026)
Following Design for Manufacturability (DFM) in July 2026, we engage contract injection molding vendors to build pilot tooling and produce all custom components by November. -
Phase 2: Modular Device Assembly (Starting Dec 2026)
Small-scale manufacturing begins, building specialized concentration units with the modular features required for our Strep A and STI trials, as well as partner assay integrations. -
Phase 3: Clinical Trials & Industry Validation (Dec 2026 Onward)
We launch parallel clinical feasibility trials for Strep A and STIs while simultaneously distributing units to industry partners for validation with their own detection assays.
Partnership & Value Expansion
-
Platform Value Expansion: Commencing Q4 2026, we explore alternative platform applications, generating performance data across multiple diagnostic, clinical, or adjacent verticals.
-
Broad Industry Engagement: Initiating in November, we drive deep awareness and target business development interest across strategic channels, establishing market demand.
-
Establishing the Foundation: Formalizing early industry interest into active pilot programs, Material Transfer Agreements (MTAs), and strategic LOIs. This turns initial outreach into a documented commercial pipeline that actively drives enterprise value.
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Read our full Investor Information & Forward-Looking Statements Disclaimer.